## Mathieu Molimard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1080466/publications.pdf

Version: 2024-02-01

118 papers 6,610 citations

57719 44 h-index 78 g-index

127 all docs

127 docs citations

times ranked

127

7408 citing authors

#	Article	lF	CITATIONS
1	Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib. Journal of Clinical Oncology, 2010, 28, 2381-2388.	0.8	802
2	Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood, 2007, 109, 3496-3499.	0.6	545
3	Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood, 2011, 117, 3733-3736.	0.6	292
4	The scientific rationale for combining long-acting $\hat{l}^22$ -agonists and muscarinic antagonists in COPD. Pulmonary Pharmacology and Therapeutics, 2010, 23, 257-267.	1.1	233
5	Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood, 2008, 112, 2024-2027.	0.6	222
6	Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. Journal of Clinical Investigation, 2016, 126, 3207-3218.	3.9	208
7	Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. European Respiratory Journal, 2017, 49, 1601794.	3.1	194
8	Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. European Respiratory Journal, 2018, 51, 1702523.	3.1	186
9	Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study. British Journal of Clinical Pharmacology, 2005, 59, 143-151.	1.1	178
10	Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. Clinica Chimica Acta, 2011, 412, 1060-1067.	0.5	151
11	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2016, 138, 367-374.e2.	1.5	128
12	High-Performance Liquid Chromatographic Method with Diode Array Detection for Identification and Quantification of the Eight New Antidepressants and Five of Their Active Metabolites in Plasma after Overdose. Therapeutic Drug Monitoring, 2003, 25, 581-587.	1.0	104
13	Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncology, The, 2016, 17, 632-641.	5.1	98
14	High throughput routine determination of 17 tyrosine kinase inhibitors by LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2018, 150, 112-120.	1.4	95
15	Quantification of Imatinib in Human Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry. Therapeutic Drug Monitoring, 2005, 27, 634-640.	1.0	94
16	Effectiveness of omalizumab (Xolair $\hat{A}^{\text{o}}$ ) in the first patients treated in real-life practice in France. Respiratory Medicine, 2008, 102, 71-76.	1.3	94
17	Gender and interindividual variability in pharmacokinetics. Drug Metabolism Reviews, 2009, 41, 408-421.	1.5	90
18	Does Omalizumab Make a Difference to the Real-life Treatment of Asthma Exacerbations?. Chest, 2013, 143, 398-405.	0.4	87

#	Article	IF	CITATIONS
19	Agreement of expert judgment in causality assessment of adverse drug reactions. European Journal of Clinical Pharmacology, 2005, 61, 169-173.	0.8	82
20	Atypical Antipsychotics. Drug Safety, 2005, 28, 35-51.	1.4	81
21	Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicology and Applied Pharmacology, 2004, 199, 52-60.	1.3	75
22	Omalizumab-induced decrease of FcÉ-RI expression in patients with severe allergic asthma. Respiratory Medicine, 2010, 104, 1608-1617.	1.3	73
23	Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumoursÂin a real-life setting. European Journal of Cancer, 2016, 57, 31-38.	1.3	71
24	Impact of Patient-Related Factors on Asthma Control. Journal of Asthma, 2008, 45, 109-113.	0.9	67
25	Inhaler Devices for Chronic Obstructive Pulmonary Disease: Insights from Patients and Healthcare Practitioners. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2015, 28, 219-228.	0.7	67
26	Interâ€expert agreement of seven criteria in causality assessment of adverse drug reactions. British Journal of Clinical Pharmacology, 2007, 64, 482-488.	1.1	66
27	A Therapeutic Drug Monitoring Algorithm for Refining the Imatinib Trough Level Obtained at Different Sampling Times. Therapeutic Drug Monitoring, 2009, 31, 579-584.	1.0	66
28	Prolonged Moderate Hyperoxia Induces Hyperresponsiveness and Airway Inflammation in Newborn Rats. Pediatric Research, 2001, 50, 515-519.	1.1	65
29	Systematic review of association between critical errors in inhalation and health outcomes in asthma and COPD. Npj Primary Care Respiratory Medicine, 2018, 28, 43.	1.1	63
30	Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS. Clinica Chimica Acta, 2010, 411, 140-146.	0.5	61
31	Structure and Function of Small Airways in Smokers: Relationship between Air Trapping at CT and Airway Inflammation. Radiology, 2003, 228, 85-94.	3.6	59
32	Estradiol Decreases the Acetylcholine-elicited Airway Reactivity in Ovariectomized Rats through an Increase in Epithelial Acetylcholinesterase Activity. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1849-1854.	2.5	58
33	Muscarinic Stimulation of Airway Smooth Muscle Cells. General Pharmacology, 1998, 31, 349-356.	0.7	57
34	Inhaled Corticosteroids and Adrenal Insufficiency. Drug Safety, 2008, 31, 769-774.	1.4	55
35	Medical and nonâ€medical direct costs of chronic low back pain in patients consulting primary care physicians in France. Fundamental and Clinical Pharmacology, 2010, 24, 101-108.	1.0	55
36	Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory. Fundamental and Clinical Pharmacology, 2013, 27, 690-697.	1.0	53

#	Article	IF	CITATIONS
37	Effects of Intermittent Femoral Nerve Injections of Bupivacaine, Levobupivacaine, and Ropivacaine on Mitochondrial Energy Metabolism and Intracellular Calcium Homeostasis in Rat Psoas Muscle. Anesthesiology, 2007, 106, 1026-1034.	1.3	52
38	A new method for assessing drug causation provided agreement with experts' judgment. Journal of Clinical Epidemiology, 2006, 59, 308-314.	2.4	51
39	High-Performance Liquid Chromatographic Method for the Simultaneous Determination of the Six HIV-Protease Inhibitors and Two Non-Nucleoside Reverse Transcriptase Inhibitors in Human Plasma. Therapeutic Drug Monitoring, 2002, 24, 417-424.	1.0	49
40	Aminoglycosides in Septic Shock. Drug Safety, 2013, 36, 217-230.	1.4	49
41	Comorbidities and COPD severity in a clinic-based cohort. BMC Pulmonary Medicine, 2018, 18, 117.	0.8	49
42	Immunotherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma: A retrospective database study in France. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1317-1326.	2.7	47
43	Underdiagnosis of Nocturnal Symptoms in Asthma in General Practice. Journal of Asthma, 2006, 43, 199-202.	0.9	46
44	Adherence to anti-inflammatory treatment for asthma in clinical practice in France. Clinical Therapeutics, 2008, 30, 1058-1068.	1.1	46
45	Drug interactions between inhaled corticosteroids and enzymatic inhibitors. European Journal of Clinical Pharmacology, 2009, 65, 743-745.	0.8	46
46	Quantification of Tricyclic Antidepressants and Monoamine Oxidase Inhibitors by High-Performance Liquid Chromatography-Tandem Mass Spectrometry in Whole Blood. Journal of Analytical Toxicology, 2007, 31, 200-207.	1.7	43
47	Quantification of Eight New Antidepressants and Five of their Active Metabolites in Whole Blood by High-Performance Liquid Chromatography-Tandem Mass Spectrometry. Journal of Analytical Toxicology, 2007, 31, 334-341.	1.7	43
48	Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study. BMC Cardiovascular Disorders, 2011, 11, 46.	0.7	42
49	Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studies. Expert Opinion on Drug Safety, 2014, 13, 573-585.	1.0	40
50	Pharmacokinetic Interaction Between High-Dose Methotrexate and Oxacillin. Therapeutic Drug Monitoring, 2002, 24, 570-572.	1.0	38
51	How to achieve good compliance and adherence with inhalation therapy. Current Medical Research and Opinion, 2005, 21, S33-S37.	0.9	38
52	Large-scale imatinib dose–concentration–effect study in CML patients under routine care conditions. Leukemia Research, 2014, 38, 764-772.	0.4	37
53	Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide. Respiratory Medicine, 2005, 99, 770-778.	1.3	34
54	Effects of armagnac extracts on human platelet function in vitro and on rat arteriovenous shunt thrombosis in vivo. Thrombosis Research, 2003, 110, 135-140.	0.8	33

#	Article	IF	CITATIONS
55	Guidance on handheld inhalers in asthma and COPD guidelines. Respiratory Medicine, 2014, 108, 694-700.	1.3	32
56	Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma. Clinica Chimica Acta, 2017, 472, 26-29.	0.5	32
57	How reimbursement databases can be used to support drug utilisation studies: example using the main French national health insurance system database. European Journal of Clinical Pharmacology, 2010, 66, 743-748.	0.8	31
58	Switching from branded to generic inhaled medications: potential impact on asthma and COPD. Expert Opinion on Drug Delivery, 2013, 10, 1597-1602.	2.4	31
59	Highly sensitive LC–MS/MS methods for urinary biological monitoring of occupational exposure to cyclophosphamide, ifosfamide, and methotrexate antineoplastic drugs and routine application. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1038, 109-117.	1.2	30
60	Life-threatening adverse drug reactions at admission to medical intensive care: aÂprospective study in aÂteaching hospital. Intensive Care Medicine, 2007, 33, 2150-2157.	3.9	29
61	Interleukin- $\hat{\Pi}^2$ -induced hyperresponsiveness to [Sar9,Met(O2)11]substance P in isolated human bronchi. European Journal of Pharmacology, 1999, 379, 87-95.	1.7	28
62	Comparison of serious inhaler technique errors made by device-na $\tilde{A}$ -ve patients using three different dry powder inhalers: a randomised, crossover, open-label study. BMC Pulmonary Medicine, 2016, 16, 12.	0.8	28
63	In vitro effects of HOE 140 in human bronchial and vascular tissue. European Journal of Pharmacology, 1995, 274, 57-64.	1.7	25
64	Factors associated with choice of psychotropic drugs used for intentional drug overdose. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 86-91.	1.8	25
65	Comparison of A60 and three glycolipid antigens in an ELISA test for tuberculosis. Clinical Microbiology and Infection, 1996, 2, 214-222.	2.8	24
66	Pharmacokinetics in special populations. Drug Metabolism Reviews, 2009, 41, 422-454.	1.5	20
67	An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients. Clinica Chimica Acta, 2017, 470, 8-13.	0.5	20
68	Increased secretion of leukemia inhibitory factor by immature airway smooth muscle cells enhances intracellular signaling and airway contractility. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2006, 291, L244-L251.	1.3	19
69	Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers. Archives of Cardiovascular Diseases, 2013, 106, 661-671.	0.7	19
70	Role of thromboxane A2 in bradykinin-induced human isolated small bronchi contraction. European Journal of Pharmacology, 1995, 278, 49-54.	1.7	18
71	Simplified ultraviolet liquid chromatographic method for determination of sertindole, dehydrosertindole and norsertindole, in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 814, 61-67.	1.2	17
72	A Method to Measure Deferasirox in Plasma Using HPLC Coupled With MS/MS Detection and its Potential Application. Therapeutic Drug Monitoring, 2010, 32, 476-481.	1.0	17

#	Article	IF	Citations
73	Prevalence and Associated Factors of Oropharyngeal Side Effects in Users of Inhaled Corticosteroids in a Real-Life Setting. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2010, 23, 91-95.	0.7	17
74	Fully Automated Analytical Method for Mycophenolic Acid Quantification in Human Plasma Using On-line Solid Phase Extraction and High Performance Liquid Chromatography With Diode Array Detection. Therapeutic Drug Monitoring, 2006, 28, 505-511.	1.0	16
75	National trends in use and costs of oral anticancer drugs in France: An 8-year population-based study. Pharmacoepidemiology and Drug Safety, 2017, 26, 1233-1241.	0.9	16
76	Long-acting $\hat{l}^2$ 2-adrenergic formoterol and salmeterol induce the apoptosis of B-chronic lymphocytic Leukaemia cells. British Journal of Haematology, 2004, 124, 141-150.	1.2	15
77	Inhalation devices for long-acting $\hat{I}^2$ 2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD. Current Medical Research and Opinion, 2007, 23, 2405-2413.	0.9	15
78	Comparison of Patient Questionnaires and Plasma Assays in Intentional Drug Overdoses. Basic and Clinical Pharmacology and Toxicology, 2004, 95, 31-37.	1.2	14
79	Increased relaxation of immature airways to $\hat{I}^2$ 2-adrenoceptor agonists is related to attenuated expression of postjunctional smooth muscle muscarinic M2 receptors. Journal of Applied Physiology, 2005, 98, 1526-1533.	1.2	14
80	Turning a Molecule into a Medicine: the Development of Indacaterol as a Novel Once-Daily Bronchodilator Treatment for Patients with COPD. Drugs, 2014, 74, 1635-1657.	4.9	14
81	Physicochemical characteristics and bronchial epithelial cell cytotoxicity of Folpan 80 WG and Myco 500, two commercial forms of folpet Particle and Fibre Toxicology, 2007, 4, 8.	2.8	13
82	SR 140333 prevents potentiation by citric acid of plasma exudation induced by histamine in airways. European Journal of Pharmacology, 1996, 308, 325-328.	1.7	12
83	Psychiatric disorders and their comorbidity in subjects with parasuicide by intentional drug overdose: Prevalence and gender differences. Psychiatry Research, 2005, 136, 93-100.	1.7	12
84	Pharmacokinetics and Pharmacodynamics of Nilotinib in Gastrointestinal Stromal Tumors. Seminars in Oncology, 2011, 38, S28-S33.	0.8	12
85	Dynamic and Rapid Changes in Viral Quasispecies by Udps in Chronic Hepatitis C Patients Receiving Telaprevir-Based Therapy. Antiviral Therapy, 2013, 18, 723-727.	0.6	12
86	Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal. Applied Health Economics and Health	1.0	12
87	Policy, 2016, 14, 579-594.  Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD. Respiratory Medicine, 2005, 99, 695-702.	1.3	11
88	Once-daily glycopyrronium via the Breezhaler $\hat{A}^{@}$ device for the treatment of COPD: pharmacological and clinical profile. Expert Review of Clinical Pharmacology, 2013, 6, 503-517.	1.3	11
89	Biomonitoring of occupational exposure to 5-FU by assaying $\hat{l}$ ±-fluoro- $\hat{l}$ 2-alanine in urine with a highly sensitive UHPLC-MS/MS method. Analyst, The, 2018, 143, 4110-4117.	1.7	11
90	Postmortem Redistribution of Two Antipsychotic Drugs, Haloperidol and Thioridazine, in the Rat. Journal of Analytical Toxicology, 2006, 30, 419-425.	1.7	10

#	Article	IF	CITATIONS
91	Accuracy of information on substance use recorded in medical charts of patients with intentional drug overdose. Psychiatry Research, 2007, 152, 73-79.	1.7	10
92	Quantification methods of folpet degradation products in plasma with HPLC-UV/DAD: Application to an in vivo toxicokinetic study in rats. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 865, 106-113.	1.2	10
93	Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia. Leukemia Research, 2009, 33, 1147-1148.	0.4	10
94	The French Levothyrox® crisis: We did the best we could but…. Therapie, 2019, 74, 431-435.	0.6	10
95	Rivaroxaban and apixaban in orthopaedics. Blood Coagulation and Fibrinolysis, 2015, 26, 925-933.	0.5	8
96	The sustainable impact of an educational approach to improve the appropriateness of laboratory test orders in the ICU. PLoS ONE, 2019, 14, e0214802.	1.1	8
97	Efficiency and safety of oxcarbazepine in mood disorders: A naturalistic study exploring the interest of plasma dosages. European Psychiatry, 2008, 23, 409-412.	0.1	7
98	Furosemide inhibits bradykinin-induced contraction of human bronchi: role of thromboxane A2 receptor antagonism. European Journal of Pharmacology, 1995, 278, 253-256.	1.7	6
99	Pharmacological Approach to Evaluate Aerosol Pulmonary Deposition. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2005, 18, 183-192.	1.2	6
100	Use of therapeutic drug monitoring in CML patients on imatinib. Blood, 2007, 110, 1701-1701.	0.6	6
101	Use of principal component analysis in the evaluation of adherence to statin treatment: a method to determine a potential target population for public health intervention. Fundamental and Clinical Pharmacology, 2011, 25, 528-533.	1.0	6
102	An observational cohort study of the use of five-grass-pollen extract sublingual immunotherapy during the 2015 pollen season in France. Allergy, Asthma and Clinical Immunology, 2018, 14, 38.	0.9	6
103	Inhibition by SR 59119A of Isoprenaline-, Forskolin- and VIP-induced Relaxation of Human Isolated Bronchi. Pulmonary Pharmacology and Therapeutics, 2000, 13, 167-174.	1.1	5
104	Insights into severe asthma control as assessed by guidelines, pulmonologist, patient, and partner. Journal of Asthma, 2010, 47, 853-859.	0.9	5
105	How to improve vaccine acceptability (evaluation, pharmacovigilance, communication, public health,) Tj ETQq $1\ 1$	0,784314	1 rgBT /Over
106	Indirect muscarinic receptor activation by pentamidine on airway smooth muscle. British Journal of Pharmacology, 1996, 119, 1131-1136.	2.7	4
107	Suicide with Cisatracurium and Thiopental: Forensic and Analytical Aspects. Journal of Analytical Toxicology, 2011, 35, 375-380.	1.7	4
108	Pharmacologically induced relaxation of tracheal smooth muscle is increased in hyperoxia-exposed 15-day-old rats. Pediatric Pulmonology, 2002, 33, 124-129.	1.0	3

#	Article	IF	Citations
109	Drug Interaction With Sunitinib and the Evidence of Therapeutic Drug Monitoring: A Case Report and Review of the Literature. Clinical Genitourinary Cancer, 2017, 15, e885-e887.	0.9	3
110	Effects of S 9977-2 on the guinea pig isolated trachea and the human isolated bronchus. Drug Development Research, 1992, 26, 147-156.	1.4	2
111	Myocardium distribution of sertindole and its metabolite dehydrosertindole in guinea-pigs. Biopharmaceutics and Drug Disposition, 2006, 27, 171-179.	1.1	2
112	Information and Communication on Risks Related to Medications and Proper Use of Medications for Healthcare Professionals and the General Public: Precautionary Principle, Risk Management, Communication During and in the Absence of Crisis Situations. Therapie, 2014, 69, 361-366.	0.6	2
113	Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study. European Journal of Cancer, 2017, 85, 39-48.	1.3	2
114	Conflicts of Interests in the Area of Healthcare Products and Technology. Current State of Affairs and Recommendations. Therapie, 2012, 67, 289-294.	0.6	1
115	Scientific Rationale for Determining the Bioequivalence of Inhaled Drugs. Clinical Pharmacokinetics, 2017, 56, 1139-1154.	1.6	1
116	Interest of pharmacoepidemiology for the study of inhaled drugs. Therapie, 2019, 74, 233-237.	0.6	1
117	How To Design a Negative Study. Chest, 2003, 123, 655-656.	0.4	0
118	Inhaled triple therapy in chronic obstructive pulmonary disease. Lancet, The, 2018, 392, 1112.	6.3	0